Orthofix earnings beat by $0.12, revenue fell short of estimates
Orthofix (OFIX) reported Q3 EPS of -$0.15, beating estimates by $0.12, but revenue of $207.86M missed expectations. The company forecasted FY 2026 revenue of $825M-$830M, below analyst consensus. OFIX stock is down 22.69% over 3 months and 47.64% over 12 months, closing at $7.87.
How this was made
The 30-second read
Why it matters
The earnings release shows a modest EPS beat but a revenue shortfall and FY guidance below consensus, likely prompting a sell‑off.
Market read
The earnings miss on revenue and weaker guidance could trigger a short‑term decline in OFIX stock.
What to watch
Potential cost‑cutting measures or upcoming product launches not mentioned in the release.
Background
Orthofix (NASDAQ:OFIX) is a medical device company; its Q3 results were released on 2026-11-09.
Ticker impact
Orthofix reported Q3 EPS beat but revenue miss and lowered FY guidance below consensus.
likely pressure as market prices in the revenue shortfall and guidance cut
First report of earnings numbers and guidance; investors typically react negatively to revenue below estimates and lowered outlook.
Market effects
May weigh on other medical device firms as guidance shortfalls raise concerns about demand.
Limited to US small‑cap medical device space.
Low global impact; primarily affects Orthofix shareholders.
Counterpoint
Some investors may see the EPS beat as a buying opportunity if they believe the revenue miss is temporary.
Key entities
- companyOrthofix
Medical device manufacturer reporting Q3 earnings.
